O-1602
Based on 2 publication(s) in Google Scholar
O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.68%
- No. CAS: 317321-41-8
- Fòrmula: C17H22O2
- Peso molecular:258.36
-
Almacenamiento:
-80°C
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Antidepressant Compound Library
HY-L108
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Inflammasomes related Compound Library
HY-L175
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) O-1602
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Neutrophil | IC50 |
33 nM
Compound: O-1602
|
Inhibition of human neutrophil migration incubated for 30 mins prior to fMLP challenge by boyden chamber assay
Inhibition of human neutrophil migration incubated for 30 mins prior to fMLP challenge by boyden chamber assay
|
[PMID: 25703248] |
O-1602 (10 μM and 100 μM; 10 days) increases intracellular calcium levels, promotes lipid accumulation, and increases the expression of CEBP-α, a key regulator of adipocyte differentiation at 100 μM[2].
O-1602 (0 μM and 10 μM; 10 days) promotes the accumulation of lipid in 3T3-L1 adipocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:3T3-L1 cells
-
Concentration:0.5 µg
-
Incubation Time:6 h
-
Result:Decreased the expression of neuropeptide Y, proopiate melanocortin, and cocaine and amphetamine regulatory transcript (CART) mRNA.
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) increases hippocampal GPR55 protein expression [1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) significantly increases DCX expression in the DG [1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) significantly decreases the number of microglia in the hippocampus [1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) increases expression levels of NLRP3, ASC, and Caspase-1 in the hippocampus [1].
O-1602 (0.1 mg/kg,ip; subchronically infused for 7 days) decreases the percentage of fat utilization over total energy consumption and decreases metabolic use of lipids leading to elevated fat deposition rates[2].
O-1602 (0.04 and 0.4 μg/h/rat, ip; for 7 days) increases the the amount of fat mass with O-1602 at the dose of 0.4 μg/h/rat[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:the model of METH-induced anxiety- and depression-like behaviors [1]
-
Dosage:10 mg/kg, once daily for 14 consecutive days
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Increased both time spent in the center area of the open field test and time exploring the open arms in the elevated plus maze test. Reduced immobility time in the forced swim and tail suspension tests.
-
Animal Model:Adult male Sprague–Dawley rats (Harlam Iberica, Barcelona, Spain) (250–275 g, 10–12 weeks old)[2]
-
Dosage:0.1, 0.5 and 1 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Did not modify food intake and body weight gain.Increased the fat mass.
Chemical Information
-
No. CAS 317321-41-8
-
Appearance Oil
-
Peso molecular 258.36
-
Fòrmula C17H22O2
-
Color White to light yellow
-
SMILES
CC1=C([C@H]2[C@@H](CCC(C)=C2)C(C)=C)C(O)=CC(O)=C1
-
Envío
Shipping with dry ice.
-
Almacenamiento
-80°C
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Activating GPR55 protects cochlear hair cells against cisplatin-induced ototoxicity via inhibiting MAPK pathway. [Abstract]2026 Apr 14;16(1):17287. PMID: 41981055 -
Heliyon
GPR55 activation improves anxiety- and depression-like behaviors of mice during methamphetamine withdrawal. [Abstract]2024 Apr 27;10(9):e30462. PMID: 38720745
Solvente y solubilidad
DMSO : 100 mg/mL (387.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months. When stored at -80°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months. When stored at -80°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months. When stored at -80°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8706 mL | 19.3528 mL | 38.7057 mL | 96.7642 mL |
| 5 mM | 0.7741 mL | 3.8706 mL | 7.7411 mL | 19.3528 mL | |
| 10 mM | 0.3871 mL | 1.9353 mL | 3.8706 mL | 9.6764 mL | |
| 15 mM | 0.2580 mL | 1.2902 mL | 2.5804 mL | 6.4509 mL | |
| 20 mM | 0.1935 mL | 0.9676 mL | 1.9353 mL | 4.8382 mL | |
| 25 mM | 0.1548 mL | 0.7741 mL | 1.5482 mL | 3.8706 mL | |
| 30 mM | 0.1290 mL | 0.6451 mL | 1.2902 mL | 3.2255 mL | |
| 40 mM | 0.0968 mL | 0.4838 mL | 0.9676 mL | 2.4191 mL | |
| 50 mM | 0.0774 mL | 0.3871 mL | 0.7741 mL | 1.9353 mL | |
| 60 mM | 0.0645 mL | 0.3225 mL | 0.6451 mL | 1.6127 mL | |
| 80 mM | 0.0484 mL | 0.2419 mL | 0.4838 mL | 1.2096 mL | |
| 100 mM | 0.0387 mL | 0.1935 mL | 0.3871 mL | 0.9676 mL |
O-1602 Related Classifications
HY-107541 Related Classifications
Powered by Bioz